An Intranasal Virus-Like Particle Vaccine Broadly Protects Mice from Multiple Subtypes of Influenza A Virus

被引:75
|
作者
Schwartzman, Louis M. [1 ]
Cathcart, Andrea L. [1 ]
Pujanauski, Lindsey M. [1 ]
Qi, Li [1 ]
Kash, John C. [1 ]
Taubenberger, Jeffery K. [1 ]
机构
[1] NIAID, Viral Pathogenesis & Evolut Sect, Infect Dis Lab, NIH, Bethesda, MD 20892 USA
来源
MBIO | 2015年 / 6卷 / 04期
基金
美国国家卫生研究院;
关键词
IMMUNE-RESPONSES; LETHAL; 1918; HEMAGGLUTININ; NEURAMINIDASE; ANTIBODIES; IMMUNIZATION; CHALLENGE; EVOLUTION; EFFICACY; FERRETS;
D O I
10.1128/mBio.01044-15
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Influenza virus infections are a global public health problem, with a significant impact of morbidity and mortality from both annual epidemics and pandemics. The current strategy for preventing annual influenza is to develop a new vaccine each year against specific circulating virus strains. Because these vaccines are unlikely to protect against an antigenically divergent strain or a new pandemic virus with a novel hemagglutinin (HA) subtype, there is a critical need for vaccines that protect against all influenza A viruses, a so-called "universal" vaccine. Here we show that mice were broadly protected against challenge with a wide variety of lethal influenza A virus infections (94% aggregate survival following vaccination) with a virus-like particle (VLP) vaccine cocktail. The vaccine consisted of a mixture of VLPs individually displaying H1, H3, H5, or H7 HAs, and vaccinated mice showed significant protection following challenge with influenza viruses expressing 1918 H1, 1957 H2, and avian H5, H6, H7, H10, and H11 hemagglutinin subtypes. These experiments suggest a promising and practical strategy for developing a broadly protective "universal" influenza vaccine. IMPORTANCE The rapid and unpredictable nature of influenza A virus evolution requires new vaccines to be produced annually to match circulating strains. Human infections with influenza viruses derived from animals can cause outbreaks that may be associated with high mortality, and such strains may also adapt to humans to cause a future pandemic. Thus, there is a large public health need to create broadly protective, or "universal," influenza vaccines that could prevent disease from a wide variety of human and animal influenza A viruses. In this study, a noninfectious virus-like particle (VLP) vaccine was shown to offer significant protection against a variety of influenza A viruses in mice, suggesting a practical strategy to develop a universal influenza vaccine.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Chikungunya Virus-Like Particle Vaccine Reply
    Chen, Grace L.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 324 (10): : 1008 - 1009
  • [22] Protection against Multiple Subtypes of Influenza Viruses by Virus-Like Particle Vaccines Based on a Hemagglutinin Conserved Epitope
    Chen, Shaoheng
    Zheng, Dan
    Li, Changgui
    Zhang, Wenjie
    Xu, Wenting
    Liu, Xueying
    Fang, Fang
    Chen, Ze
    BIOMED RESEARCH INTERNATIONAL, 2015, 2015
  • [23] The Immunogenicity and Efficacy of a Virus-like Particle Vaccine Candidate against Respiratory Syncytial Virus in Mice
    McGinnes, L.
    Murawski, M.
    Finberg, R.
    Kurt-Jones, E.
    Frair, A.
    Mahmood, K.
    Wu, Y.
    Pushko, P.
    Heaton, P.
    Morrison, T.
    VACCINE, 2008,
  • [24] Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus
    Quan, Fu-Shi
    Huang, Chunzi
    Compans, Richard W.
    Kang, Sang-Moo
    JOURNAL OF VIROLOGY, 2007, 81 (07) : 3514 - 3524
  • [25] Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge
    Galarza, JM
    Latham, T
    Cupo, A
    VIRAL IMMUNOLOGY, 2005, 18 (01) : 244 - 251
  • [26] Neuraminidase expressing virus-like particle vaccine provides effective cross protection against influenza virus
    Kim, Ki-Hye
    Lee, Young-Tae
    Park, Soojin
    Jung, Yu-Jin
    Lee, Youri
    Ko, Eun-Ju
    Kim, Yu-Jin
    Li, Xuguang
    Kang, Sang-Moo
    VIROLOGY, 2019, 535 : 179 - 188
  • [27] A novel intranasal virus-like particle (VLP) vaccine designed to protect against the pandemic 1918 influenza a virus (H1N1)
    Matassov, Demetrius
    Cupo, Albert
    Galarza, Jose M.
    VIRAL IMMUNOLOGY, 2007, 20 (03) : 441 - 452
  • [28] Virus-like particle vaccine by intranasal vaccination elicits protective immunity against respiratory syncytial viral infection in mice
    Cai, Mengying
    Wang, Cheng
    Li, Yufeng
    Gu, Hongjing
    Sun, Sujing
    Duan, Yueqiang
    Lai, Chengcai
    Wang, Keyu
    Yang, Xiaolan
    Xing, Li
    Zhang, Peirui
    Wang, Zhaohai
    Zhang, Shaogeng
    Guo, Xiaodong
    Liu, Shubing
    Tong, Yigang
    Wang, Xiliang
    Yang, Penghui
    ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2017, 49 (01) : 74 - 82
  • [29] Protection conferred by virus-like particle vaccines against respiratory syncytial virus infection in mice by intranasal vaccination
    Gu, Hongjing
    Li, Tieling
    Han, Lina
    Zhu, Ping
    Zhang, Peirui
    Zhang, Shaogeng
    Sun, Sujing
    Duan, Yueqiang
    Xing, Li
    Zhao, Zhongpeng
    Lai, Chengcai
    Wen, Bohai
    Wang, Xiliang
    Yang, PengHui
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2015, 11 (04) : 1057 - 1064
  • [30] A virus-like particle vaccine candidate for influenza A virus based on multiple conserved antigens presented on hepatitis B tandem core particles
    Ramirez, Alejandro
    Morris, Stephen
    Maucourant, Sophie
    D'Ascanio, Isabella
    Crescente, Vincenzo
    Lu, I-Na
    Farinelle, Sophie
    Muller, Claude P.
    Whelan, Michael
    Rosenberg, William
    VACCINE, 2018, 36 (06) : 873 - 880